-MUSE(TM) System provides a new effective, intuitive and incisionless procedure for GERD-
OMER, Israel, June 18, 2014 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and procedures announced today that the MUSE(TM) System will be presented as part of the Amazing Technologies Symposium at the European Association for Endoscopic Surgery's (EAES) 14th World Congress of Endoscopic Surgery (WCES2014), taking place June 25-28, 2014 at the Palais des Congrès, in Paris, France.
Medigus has merged recent breakthroughs in visualization, ultrasound and surgical stapling capabilities into one platform, the MUSE(TM) System, to enable safe, incisionless procedures within the GI tract. The MUSE(TM) procedure is intuitive and can be performed by a single surgeon or endoscopist in the endoscopy suite. The device performs a surgical anterior fundoplication with standard surgical staples in a less invasive way, helping enhance patient care.
MUSE(TM) Oral Presentation at EAES
Amazing Technologies Symposium
Wednesday, June 25, 2014 from 3:54-4:00pm
- Oral Presentation: NEXT GENERATION PLATFORM CREATES TRANSORAL ANTERIOR FUNDOPLICATION FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) Aviel Roy-Shapira, MD, Menashe Sonnenschein, Amir Govrin, Yoav Mintz, MD, Santiago Horgan, MD
"We are proud to be highlighted as one of the cutting edge technologies for minimally invasive surgery at the upcoming World Congress of Endoscopic Surgery," said Chris Rowland, CEO, Medigus. "The MUSE(TM) System uniquely allows doctors to use a non-invasive treatment for GERD to enhance patient care. We've treated GERD patients in leading hospitals in the U.S and Europe and look forward to working with physicians across markets to continue to bring our breakthrough technology to more patients globally," Rowland added.
The European Association for Endoscopic Surgery's (EAES) was founded in 1990 and since then has become a growing and dynamic organization that will continue to play a leading role in the future progress of endoscopic surgery and advanced technology dependent interventions. Aside from organizing annual top level European congresses in different European countries, the EAES activities in the research, development, training and publication are effected through its various committees: Educational & Training, Research (multi centre studies and clinical trials), Technology (R&D in instrumentation, ancillary equipment, telerobotics and telecommunication) and Journal & Publication (publication of original articles and state of the art reviews). The EAES has taken the lead in setting up Consensus development conferences which are now a regular feature of the congresses of the association.
Over the years the EAES has established a familiar name position in the growing world of endoscopy.
About The 14th World Congress of Endoscopic Surgery
The 14th World Congress of Endoscopic Surgery will be held in Paris, June 25-28, 2014 under the auspices of the European Association for Endoscopic Surgery (EAES) in conjonction with the SFCE (Société Française de Chirurgie Endoscopique) and the International Society for Laparoscopic ColoRectal Surgery (ISLCRS).
As this is a World Congress, other societies either under the umbrella of the International Federation of Societies of Endoscopic Surgeons (IFSES), including SAGES (Society of American Gastrointestinal and Endoscopic Surgeons), the Endoscopic and Laparoscopic Surgeons of Asia (ELSA), Federación Latino Americana de Cirugia (FELAC), and Asociacion Latinoamericano de Cirugia Endoscopica (ALACE), or independent, such as, the Asia Pacific and European hernia societies, will be joining us.
MUSE(TM) is an intuitive endoscopic platform that consists of a single use surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder. The single operator system, performs a surgical anterior fundoplication with standard surgical staples in a less invasive way, compared to other surgical procedures.
Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE(TM) system enables endoscopists to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE(TM) system does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE(TM) system (previously known as SRS(TM) system for transoral fundoplication) has received FDA clearance and CE mark. Medigus is traded on the TASE (Tel Aviv Stock Exchange). To learn more about the company's minimally invasive technology platform, please visit http://www.medigus.com/.
INVESTOR RELATIONS CONTACT: